Improvement of apathy in early Parkinson’s disease
Abstract Apathy is a disabling symptom in Parkinson’s disease (PD). The effect of dopaminergic treatment on apathy is inconsistent, depending on the stage of the disease, the type of apathy and strongly influenced by placebo effect. Our study assessed the evolution of a cohort of 86 de novo, drug na...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-04-01
|
| Series: | npj Parkinson's Disease |
| Online Access: | https://doi.org/10.1038/s41531-025-00937-w |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850139250437128192 |
|---|---|
| author | A. Castrioto E. Schmitt M. Anheim S. Meoni H. Klinger D. Sourd P. Pelissier E. Lhommée A. Bichon C. Tranchant E. Moro V. Fraix S. Thobois P. Krack |
| author_facet | A. Castrioto E. Schmitt M. Anheim S. Meoni H. Klinger D. Sourd P. Pelissier E. Lhommée A. Bichon C. Tranchant E. Moro V. Fraix S. Thobois P. Krack |
| author_sort | A. Castrioto |
| collection | DOAJ |
| description | Abstract Apathy is a disabling symptom in Parkinson’s disease (PD). The effect of dopaminergic treatment on apathy is inconsistent, depending on the stage of the disease, the type of apathy and strongly influenced by placebo effect. Our study assessed the evolution of a cohort of 86 de novo, drug naive PD patients for 4 years, after dopaminergic treatment introduction. The main objective of the study was the change of apathy from baseline to follow-up and secondary outcomes were the change of other neuropsychiatric symptoms. At 4 years there was an improvement of apathy (p = 0.002), mainly driven by improvement of baseline apathy (p = 0.001). This was associated with an improvement of anxiety (p = 0.001), an increase in hyperdopaminergic behavior including nocturnal hyperactivity with consecutive diurnal sleepiness (p = 0.001 and p < 0.001), independently of the presence of apathy at baseline. These findings confirm, in a large real-life cohort, that dopaminergic treatment improves motivational apathy in early PD. |
| format | Article |
| id | doaj-art-e19d1803e01b4ea5be81b73d5a40d25b |
| institution | OA Journals |
| issn | 2373-8057 |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | npj Parkinson's Disease |
| spelling | doaj-art-e19d1803e01b4ea5be81b73d5a40d25b2025-08-20T02:30:22ZengNature Portfolionpj Parkinson's Disease2373-80572025-04-011111810.1038/s41531-025-00937-wImprovement of apathy in early Parkinson’s diseaseA. Castrioto0E. Schmitt1M. Anheim2S. Meoni3H. Klinger4D. Sourd5P. Pelissier6E. Lhommée7A. Bichon8C. Tranchant9E. Moro10V. Fraix11S. Thobois12P. Krack13Univ. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Neurology DepartmentUniv. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Neurology DepartmentDépartement de Neurologie, Hôpital de Hautepierre, Hôpitaux Universitaires de StrasbourgUniv. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Neurology DepartmentHospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Réanimation Neurologique, Hôpital Louis Pradel, Réanimation ChirurgicaleUniv. Grenoble Alpes, Data Engineering Unit, Public Health Department, Grenoble Alpes University HospitalUniv. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Neurology DepartmentUniv. Grenoble Alpes, UMR CNRS 5105 Neuropsychology and NeuroCognition, CHU Grenoble Alpes, Dept of NeuroRehabilitation South HospitalCHU Grenoble-Alpes, Service universitaire de Gériatrie et Gérontologie CliniqueDépartement de Neurologie, Hôpital de Hautepierre, Hôpitaux Universitaires de StrasbourgUniv. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Neurology DepartmentUniv. Grenoble Alpes, Inserm, U1216, CHU Grenoble Alpes, Grenoble Institut Neurosciences, Neurology DepartmentHospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Neurologie C, Parkinson expert center, Bron, France France; NS-PARKDepartment of Neurology, Inselspital, University Hospital BernAbstract Apathy is a disabling symptom in Parkinson’s disease (PD). The effect of dopaminergic treatment on apathy is inconsistent, depending on the stage of the disease, the type of apathy and strongly influenced by placebo effect. Our study assessed the evolution of a cohort of 86 de novo, drug naive PD patients for 4 years, after dopaminergic treatment introduction. The main objective of the study was the change of apathy from baseline to follow-up and secondary outcomes were the change of other neuropsychiatric symptoms. At 4 years there was an improvement of apathy (p = 0.002), mainly driven by improvement of baseline apathy (p = 0.001). This was associated with an improvement of anxiety (p = 0.001), an increase in hyperdopaminergic behavior including nocturnal hyperactivity with consecutive diurnal sleepiness (p = 0.001 and p < 0.001), independently of the presence of apathy at baseline. These findings confirm, in a large real-life cohort, that dopaminergic treatment improves motivational apathy in early PD.https://doi.org/10.1038/s41531-025-00937-w |
| spellingShingle | A. Castrioto E. Schmitt M. Anheim S. Meoni H. Klinger D. Sourd P. Pelissier E. Lhommée A. Bichon C. Tranchant E. Moro V. Fraix S. Thobois P. Krack Improvement of apathy in early Parkinson’s disease npj Parkinson's Disease |
| title | Improvement of apathy in early Parkinson’s disease |
| title_full | Improvement of apathy in early Parkinson’s disease |
| title_fullStr | Improvement of apathy in early Parkinson’s disease |
| title_full_unstemmed | Improvement of apathy in early Parkinson’s disease |
| title_short | Improvement of apathy in early Parkinson’s disease |
| title_sort | improvement of apathy in early parkinson s disease |
| url | https://doi.org/10.1038/s41531-025-00937-w |
| work_keys_str_mv | AT acastrioto improvementofapathyinearlyparkinsonsdisease AT eschmitt improvementofapathyinearlyparkinsonsdisease AT manheim improvementofapathyinearlyparkinsonsdisease AT smeoni improvementofapathyinearlyparkinsonsdisease AT hklinger improvementofapathyinearlyparkinsonsdisease AT dsourd improvementofapathyinearlyparkinsonsdisease AT ppelissier improvementofapathyinearlyparkinsonsdisease AT elhommee improvementofapathyinearlyparkinsonsdisease AT abichon improvementofapathyinearlyparkinsonsdisease AT ctranchant improvementofapathyinearlyparkinsonsdisease AT emoro improvementofapathyinearlyparkinsonsdisease AT vfraix improvementofapathyinearlyparkinsonsdisease AT sthobois improvementofapathyinearlyparkinsonsdisease AT pkrack improvementofapathyinearlyparkinsonsdisease |